74 related articles for article (PubMed ID: 26134970)
1. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine.
Li Z; Tan F; Liewehr DJ; Steinberg SM; Thiele CJ
J Natl Cancer Inst; 2010 Jun; 102(11):758-70. PubMed ID: 20463309
[TBL] [Abstract][Full Text] [Related]
3. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating.
Chen RL; Reynolds CP; Seeger RC
Cancer Immunol Immunother; 2000 Feb; 48(11):603-12. PubMed ID: 10663607
[TBL] [Abstract][Full Text] [Related]
4. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.
Doronin II; Vishnyakova PA; Kholodenko IV; Ponomarev ED; Ryazantsev DY; Molotkovskaya IM; Kholodenko RV
BMC Cancer; 2014 Apr; 14():295. PubMed ID: 24773917
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathways.
Brouxhon SM; Kyrkanides S; Teng X; Raja V; O'Banion MK; Clarke R; Byers S; Silberfeld A; Tornos C; Ma L
Clin Cancer Res; 2013 Jun; 19(12):3234-46. PubMed ID: 23620408
[TBL] [Abstract][Full Text] [Related]
6. The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.
Golden E; Rashwan R; Woodward EA; Sgro A; Wang E; Sorolla A; Waryah C; Tie WJ; Cuyàs E; Ratajska M; Kardaś I; Kozlowski P; Johnstone EKM; See HB; Duffy C; Parry J; Lagerborg KA; Czapiewski P; Menendez JA; Gorczyński A; Wasag B; Pfleger KDG; Curtis C; Lee BK; Kim J; Cursons J; Pavlos NJ; Biernat W; Jain M; Woo AJ; Redfern A; Blancafort P
Nat Commun; 2021 Mar; 12(1):1920. PubMed ID: 33772001
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.
Uttenreuther-Fischer MM; Huang CS; Reisfeld RA; Yu AL
Cancer Immunol Immunother; 1995 Jul; 41(1):29-36. PubMed ID: 7641217
[TBL] [Abstract][Full Text] [Related]
8. Emodin Alleviates Hydrogen Peroxide-Induced Inflammation and Oxidative Stress via Mitochondrial Dysfunction by Inhibiting the PI3K/mTOR/GSK3
Li R; Liu W; Ou L; Gao F; Li M; Wang L; Wei P; Miao F
Biomed Res Int; 2020; 2020():1562915. PubMed ID: 32832542
[TBL] [Abstract][Full Text] [Related]
9. Novel cellular systems unveil mucosal melanoma initiating cells and a role for PI3K/Akt/mTOR pathway in mucosal melanoma fitness.
Monti M; Benerini Gatta L; Bugatti M; Pezzali I; Picinoli S; Manfredi M; Lavazza A; Vanella VV; De Giorgis V; Zanatta L; Missale F; Lonardi S; Zanetti B; Bozzoni G; Cadei M; Abate A; Vergani B; Balzarini P; Battocchio S; Facco C; Turri-Zanoni M; Castelnuovo P; Nicolai P; Fonsatti E; Leone BE; Marengo E; Sigala S; Ronca R; Perego M; Lombardi D; Vermi W
J Transl Med; 2024 Jan; 22(1):35. PubMed ID: 38191367
[TBL] [Abstract][Full Text] [Related]
10. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe NW; Huang M; Dalton GN; Alexe G; Schaefer DA; Geraghty AC; Robichaud AL; Conway AS; Khalid D; Mader MM; Belk JA; Ross KN; Sheffer M; Linde MH; Ly N; Yao W; Rotiroti MC; Smith BAH; Wernig M; Bertozzi CR; Monje M; Mitsiades CS; Majeti R; Satpathy AT; Stegmaier K; Majzner RG
Nat Cancer; 2022 Aug; 3(8):976-993. PubMed ID: 35817829
[TBL] [Abstract][Full Text] [Related]
11. Silencing of the
Bugara B; Durbas M; Kudrycka M; Malinowska A; Horwacik I; Rokita H
Front Pharmacol; 2024; 15():1351536. PubMed ID: 38495105
[TBL] [Abstract][Full Text] [Related]
12. Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway.
Zhao P; Aguilar AE; Lee JY; Paul LA; Suh JH; Puri L; Zhang M; Beckstead J; Witkowski A; Ryan RO; Saba JD
Invest New Drugs; 2018 Oct; 36(5):743-754. PubMed ID: 29335887
[TBL] [Abstract][Full Text] [Related]
13. GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experiments.
Feng Y; Jiang Y; Hao F
J Transl Med; 2021 Aug; 19(1):373. PubMed ID: 34461940
[TBL] [Abstract][Full Text] [Related]
14. Cell survival signaling in neuroblastoma.
Megison ML; Gillory LA; Beierle EA
Anticancer Agents Med Chem; 2013 May; 13(4):563-75. PubMed ID: 22934706
[TBL] [Abstract][Full Text] [Related]
15. A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.
Westhoff MA; Karpel-Massler G; Brühl O; Enzenmüller S; La Ferla-Brühl K; Siegelin MD; Nonnenmacher L; Debatin KM
Mol Cell Ther; 2014; 2():32. PubMed ID: 26056598
[TBL] [Abstract][Full Text] [Related]
16. RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype.
Sorokin M; Kholodenko I; Kalinovsky D; Shamanskaya T; Doronin I; Konovalov D; Mironov A; Kuzmin D; Nikitin D; Deyev S; Buzdin A; Kholodenko R
Biomedicines; 2020 May; 8(6):. PubMed ID: 32486168
[TBL] [Abstract][Full Text] [Related]
17. The role of intracellular calcium for the development and treatment of neuroblastoma.
Satheesh NJ; Büsselberg D
Cancers (Basel); 2015 May; 7(2):823-48. PubMed ID: 26010602
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Oxazepine Derivatives as Akt/ROCK Inhibitors for Growth Arrest and Differentiation Induction in Neuroblastoma Treatment.
Che J; Bing S; Lu J; Jin Z; Gao J; Sheng H; Li D; Yang B; He Q; Ying M; Dong X
J Med Chem; 2023 Oct; 66(19):13530-13555. PubMed ID: 37749892
[TBL] [Abstract][Full Text] [Related]
19. Perifosine as a potential novel anti-telomerase therapy.
Holohan B; Hagiopian MM; Lai TP; Huang E; Friedman DR; Wright WE; Shay JW
Oncotarget; 2015 Sep; 6(26):21816-26. PubMed ID: 26307677
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent.
Shen J; Hong Y; Zhao Q; Zhang JL
Tumour Biol; 2016 Jan; 37(1):1025-33. PubMed ID: 26269112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
